149 related articles for article (PubMed ID: 12901424)
1. Resistance emergence among P. aenrginosa in a rat thigh-abscess model. Comparison of imipenem and meropenem treatment.
Karadenizli A; Kolayli F; Okay E; Ergen K; Oz S; Savli H; Leblebicioglu H; Vahaboglu H
New Microbiol; 2003 Jul; 26(3):275-80. PubMed ID: 12901424
[TBL] [Abstract][Full Text] [Related]
2. Potency of carbapenems for the prevention of carbapenem-resistant mutants of Pseudomonas aeruginosa: the high potency of a new carbapenem doripenem.
Sakyo S; Tomita H; Tanimoto K; Fujimoto S; Ike Y
J Antibiot (Tokyo); 2006 Apr; 59(4):220-8. PubMed ID: 16830889
[TBL] [Abstract][Full Text] [Related]
3. Comparative in vivo efficacy of meropenem, imipenem, and cefepime against Pseudomonas aeruginosa expressing MexA-MexB-OprM efflux pumps.
Ong CT; Tessier PR; Li C; Nightingale CH; Nicolau DP
Diagn Microbiol Infect Dis; 2007 Feb; 57(2):153-61. PubMed ID: 16930925
[TBL] [Abstract][Full Text] [Related]
4. Carbapenem resistance mechanisms in Pseudomonas aeruginosa: alterations of porin OprD and efflux proteins do not fully explain resistance patterns observed in clinical isolates.
El Amin N; Giske CG; Jalal S; Keijser B; Kronvall G; Wretlind B
APMIS; 2005 Mar; 113(3):187-96. PubMed ID: 15799762
[TBL] [Abstract][Full Text] [Related]
5. Meropenem and imipenem activity against Pseudomonas aeruginosa isolates from the MYSTIC Program.
Turner PJ
Diagn Microbiol Infect Dis; 2006 Nov; 56(3):341-4. PubMed ID: 17049798
[TBL] [Abstract][Full Text] [Related]
6. Comparison in a rat thigh abscess model of imipenem, meropenem and cefoperazone-sulbactam against Acinetobacter baumannii strains in terms of bactericidal efficacy and resistance selection.
Fetiye K; Karadenizli A; Okay E; Oz S; Budak F; Gundes S; Vahaboglu H
Ann Clin Microbiol Antimicrob; 2004 Jan; 3():2. PubMed ID: 14713318
[TBL] [Abstract][Full Text] [Related]
7. Detection of outer membrane porin protein, an imipenem influx channel, in Pseudomonas aeruginosa clinical isolates.
Naenna P; Noisumdaeng P; Pongpech P; Tribuddharat C
Southeast Asian J Trop Med Public Health; 2010 May; 41(3):614-24. PubMed ID: 20578550
[TBL] [Abstract][Full Text] [Related]
8. Emergence of resistance to carbapenem antibiotics in Pseudomonas aeruginosa.
Margaret BS; Drusano GL; Standiford HC
J Antimicrob Chemother; 1989 Sep; 24 Suppl A():161-7. PubMed ID: 2509413
[TBL] [Abstract][Full Text] [Related]
9. Doripenem versus Pseudomonas aeruginosa in vitro: activity against characterized isolates, mutants, and transconjugants and resistance selection potential.
Mushtaq S; Ge Y; Livermore DM
Antimicrob Agents Chemother; 2004 Aug; 48(8):3086-92. PubMed ID: 15273124
[TBL] [Abstract][Full Text] [Related]
10. [Shall we report the carbapenem resistance in Pseudomonas aeruginosa and Acinetobacter baumannii strains detected by BD Phoenix system?].
Oğünç D; Ongüt G; Ozen NS; Baysan BO; Günseren F; Dağlar D; Demirbakan H; Gültekin M
Mikrobiyol Bul; 2010 Apr; 44(2):197-202. PubMed ID: 20549953
[TBL] [Abstract][Full Text] [Related]
11. The effects of group 1 versus group 2 carbapenems on imipenem-resistant Pseudomonas aeruginosa: an ecological study.
Carmeli Y; Lidji SK; Shabtai E; Navon-Venezia S; Schwaber MJ
Diagn Microbiol Infect Dis; 2011 Jul; 70(3):367-72. PubMed ID: 21683268
[TBL] [Abstract][Full Text] [Related]
12. Role of outer membrane protein OprD and penicillin-binding proteins in resistance of Pseudomonas aeruginosa to imipenem and meropenem.
Farra A; Islam S; Strålfors A; Sörberg M; Wretlind B
Int J Antimicrob Agents; 2008 May; 31(5):427-33. PubMed ID: 18375104
[TBL] [Abstract][Full Text] [Related]
13. In vitro and in vivo evaluation of BO-2727 against imipenem- and/or meropenem-resistant Pseudomonas aeruginosa.
Shibata K; Adachi Y; Kato E; Nagano R; Fuse A; Hashizume T; Ohtake N; Okamoto O; Nakagawa S
J Antibiot (Tokyo); 1997 Feb; 50(2):135-8. PubMed ID: 9099222
[TBL] [Abstract][Full Text] [Related]
14. Predicting doripenem susceptibility based on meropenem and imipenem interpretation for Pseudomonas aeruginosa.
Hagihara M; Kuti JL; Nicolau DP
Diagn Microbiol Infect Dis; 2012 Mar; 72(3):258-62. PubMed ID: 22209563
[TBL] [Abstract][Full Text] [Related]
15. Comparative activity of meropenem against Pseudomonas aeruginosa strains with well-characterized resistance mechanisms.
Livermore DM; Yang YJ
J Antimicrob Chemother; 1989 Sep; 24 Suppl A():149-59. PubMed ID: 2553657
[TBL] [Abstract][Full Text] [Related]
16. Characterization of clinical isolates of Pseudomonas aeruginosa heterogeneously resistant to carbapenems.
Pournaras S; Ikonomidis A; Markogiannakis A; Spanakis N; Maniatis AN; Tsakris A
J Med Microbiol; 2007 Jan; 56(Pt 1):66-70. PubMed ID: 17172519
[TBL] [Abstract][Full Text] [Related]
17. Correlation between meropenem and doripenem use density and the incidence of carbapenem-resistant Pseudomonas aeruginosa.
Shigemi A; Matsumoto K; Yaji K; Shimodozono Y; Takeda Y; Miyanohara H; Kawamura H; Orita M; Tokuda K; Nishi J; Yamada K
Int J Antimicrob Agents; 2009 Dec; 34(6):589-91. PubMed ID: 19748231
[TBL] [Abstract][Full Text] [Related]
18. [Carbapenem resistance determined by metalloenzymes in clinical isolates of Pseudomonas aeruginosa].
Sánchez A; Salso S; Culebras E; Picazo JJ
Rev Esp Quimioter; 2004 Dec; 17(4):336-40. PubMed ID: 15696224
[TBL] [Abstract][Full Text] [Related]
19. In vitro activities of three carbapenems against recent bacterial isolates from severely ill patients at Swedish hospitals.
Fraenkel CJ; Ullberg M; Bernander S; Ericson E; Larsson P; Rydberg J; Törnqvist E; Melhus A
Scand J Infect Dis; 2006; 38(10):853-9. PubMed ID: 17008228
[TBL] [Abstract][Full Text] [Related]
20. Levofloxacin/imipenem prevents the emergence of high-level resistance among Pseudomonas aeruginosa strains already lacking susceptibility to one or both drugs.
Lister PD; Wolter DJ; Wickman PA; Reisbig MD
J Antimicrob Chemother; 2006 May; 57(5):999-1003. PubMed ID: 16513915
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
